Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.

TitleOutcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
Publication TypeJournal Article
Year of Publication2017
AuthorsXu B, Tallini G, Scognamiglio T, Roman BR, R Tuttle M, Ghossein RA
JournalThyroid
Volume27
Issue4
Pagination512-517
Date Published2017 04
ISSN1557-9077
KeywordsAdenocarcinoma, Follicular, Adult, Aged, Aged, 80 and over, Carcinoma, Papillary, Clinical Decision-Making, Female, Humans, Iodine Radioisotopes, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Retrospective Studies, Thyroid Neoplasms, Thyroidectomy, Treatment Outcome, Tumor Burden, Young Adult
Abstract

BACKGROUND: In 2016, encapsulated follicular variant of papillary thyroid carcinoma without invasion was renamed "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" (NIFTP) in order to reduce overtreatment of this indolent tumor. However, many endocrinologists remain uneasy about managing large (≥4 cm) NIFTP conservatively without radioactive iodine (RAI) therapy. The objectives of this study are to characterize the clinicopathologic characteristics and outcome of large NIFTP in order to assist therapeutic decision making.

METHODS: The pathology databases of four tertiary hospitals were searched for large (≥4 cm) NIFTP. Cases with separate foci of carcinoma were excluded. Seventy-nine cases fulfilled the inclusion criteria. Among them, 56 (71%) had at least two years of clinical follow-up (FU), and 49 (62%) had four or more years of FU. The clinicopathologic characteristics were reviewed and documented by four endocrine pathologists.

RESULTS: The median size of the NIFTP was 4.5 cm (range 4.0-8.0 cm). The entire capsule was sampled in 50 (63%) tumors, while in the remaining 29 (37%) cases, it was submitted representatively, with a median of 2.1 blocks per centimeter of tumor examined. Large NIFTP had a female preponderance with a male:female ratio of 1:1.8, and presented at a median age of 49 years. There were no lymph node metastases at diagnosis in any of the patients, and none of the patients (n = 25) in whom nodal tissue was available for microscopic examination had positive findings. Twenty-six (33%) underwent thyroid lobectomy alone, and 37 (47%) did not receive RAI ablation. No recurrence was observed in the entire cohort, including all 32 patients with two or more years of FU who did not receive RAI therapy (median FU: 6.7 years). Among patients with four or more years of FU, all 25 individuals without RAI therapy did not recur, with a median FU of 11.2 years. Patients with a larger tumor size tended to receive postoperative RAI ablation (p = 0.001).

CONCLUSIONS: Similar to their small counterparts, large NIFTP appear to have an extremely low risk of recurrence (zero in this cohort), even when treated conservatively without RAI therapy. Surgical treatment alone, including lobectomy, appears to be adequate for large NIFTP.

DOI10.1089/thy.2016.0649
Alternate JournalThyroid
PubMed ID28136139
PubMed Central IDPMC5385447
Grant ListP50 CA172012 / CA / NCI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
Related Faculty: 
Theresa Scognamiglio, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700